Centessa Pharmaceuticals (CNTA) Change in Accured Expenses (2020 - 2026)

Centessa Pharmaceuticals (CNTA) has 7 years of Change in Accured Expenses data on file, last reported at -$9.0 million in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$9.0 million, up 69.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $5.3 million (up 101.78% YoY), and the FY2025 annual result was -$15.2 million, down 166.82% from the prior year.
• Change in Accured Expenses declined to -$9.0 million in Q1 2026 per CNTA's latest filing, from $12.1 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $32.7 million in Q4 2024 and troughed at -$29.6 million in Q1 2025.
• A 5-year average of $235529.4 and a median of $2.0 million in 2023 frame the typical range for Change in Accured Expenses.
• On a YoY basis, Change in Accured Expenses climbed as much as 1501.47% in 2024 and fell as far as 2706.12% in 2024.
• A 5-year view of Change in Accured Expenses shows it stood at -$4.8 million in 2022, then surged by 142.28% to $2.0 million in 2023, then jumped by 1501.47% to $32.7 million in 2024, then sank by 62.91% to $12.1 million in 2025, then sank by 174.25% to -$9.0 million in 2026.
• Business Quant data shows CNTA's Change in Accured Expenses at -$9.0 million in Q1 2026, $12.1 million in Q4 2025, and -$689000.0 in Q3 2025.